A hypolipidemic agent
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Etofibrate

Item No. 21022

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3-pyridinecarboxylic acid, 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]ethyl ester
CAS Number
31637-97-5
Synonyms
  • Nicotinic Acid
Molecular Formula
C18H18ClNO5
Formula Weight
363.8
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 50 mg/mlDMSO: 80 mg/mlEthanol: 80 mg/mlEthanol:PBS(pH 7.2) (1:5): 0.1 mg/ml
λmax
222, 263 nm
SMILES
ClC1=CC=C(OC(C)(C)C(OCCOC(C2=CC=CN=C2)=O)=O)C=C1
InChi Code
InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3
InChi Key
XXRVYAFBUDSLJX-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $36

    Add

    10 mg

    $53

    Add

    25 mg

    $86

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Etofibrate is a combination of niacin and clofibrate (Item No. 10956) that acts as a hypolipidemic agent.1 In vivo, etofibrate decreases plasma cholesterol and triglyceride concentrations and increases bile cholesterol content in rats.1,2 It also decreases thromboxane formation, platelet aggregation, and plasma viscosity and inhibits neointima formation in a carotid artery balloon injury rat model.3 Formulations containing etofibrate have been used to treat hyperlipidemia.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Bocos, C., Orozco, E., Castro, M., et al. Effect of etofibrate on bile production in the normolipidemic rat. Gen. Pharmacol. 26(3), 537-542 (1995).

    2. Herrera, E., Lasunción, M.A., Castro, M., et al. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. Biochim. Biophys. Acta 963(1), 42-52 (1988).

    3. Kinscherf, R., Metz, J., and Wülfroth, P. Etofibrate suppresses neointima formation of the ballooned common carotid artery of rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 352(4), 424-428 (1995).